Hsiao-Yen Ma1, Gen Yamamoto1, Jun Xu1, Xiao Liu1, Daniel Karin2, Ju Youn Kim3, Ludmil B Alexandrov4, Yukinori Koyama2, Takahiro Nishio2, Chris Benner2, Sven Heinz2, Sara B Rosenthal2, Shuang Liang2, Mengxi Sun2, Gabriel Karin2, Peng Zhao3, Pnina Brodt5, Iain H Mckillop6, Oswald Quehenberger2, Ed Dennis2, Alan Saltiel3, Hidekazu Tsukamoto7, Bin Gao8, Michael Karin3, David A Brenner2, Tatiana Kisseleva9. 1. Department of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Surgery, University of California San Diego, La Jolla, CA, USA. 2. Department of Medicine, University of California San Diego, La Jolla, CA, USA. 3. Department of Pharmacology, University of California San Diego, La Jolla, CA, USA. 4. Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. 5. Department of Medicine, McGill University and the McGill University Health Center, Montreal, QC, Canada. 6. Department of Biology, University of North Carolina at Charlotte, Charlotte, NC, USA. 7. Southern California Research Center for ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine of USC, Los Angeles, CA, USA; Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 8. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA. 9. Department of Surgery, University of California San Diego, La Jolla, CA, USA. Electronic address: tkisseleva@ucsd.edu.
Abstract
BACKGROUND & AIMS: Chronic alcohol consumption is a leading risk factor for the development of hepatocellular carcinoma (HCC), which is associated with a marked increase in hepatic expression of pro-inflammatory IL-17A and its receptor IL-17RA. METHODS: Genetic deletion and pharmacological blocking were used to characterize the role of IL-17A/IL-17RA signaling in the pathogenesis of HCC in mouse models and human specimens. RESULTS: We demonstrate that the global deletion of the Il-17ra gene suppressed HCC in alcohol-fed diethylnitrosamine-challenged Il-17ra-/- and major urinary protein-urokinase-type plasminogen activator/Il-17ra-/- mice compared with wild-type mice. When the cell-specific role of IL-17RA signaling was examined, the development of HCC was decreased in both alcohol-fed Il-17raΔMΦ and Il-17raΔHep mice devoid of IL-17RA in myeloid cells and hepatocytes, but not in Il-17raΔHSC mice (deficient in IL-17RA in hepatic stellate cells). Deletion of Il-17ra in myeloid cells ameliorated tumorigenesis via suppression of pro-tumorigenic/inflammatory and pro-fibrogenic responses in alcohol-fed Il-17raΔMΦ mice. Remarkably, despite a normal inflammatory response, alcohol-fed Il-17raΔHep mice developed the fewest tumors (compared with Il-17raΔMΦ mice), with reduced steatosis and fibrosis. Steatotic IL-17RA-deficient hepatocytes downregulated the expression of Cxcl1 and other chemokines, exhibited a striking defect in tumor necrosis factor (TNF)/TNF receptor 1-dependent caspase-2-SREBP1/2-DHCR7-mediated cholesterol synthesis, and upregulated the production of antioxidant vitamin D3. The pharmacological blocking of IL-17A/Th-17 cells using anti-IL-12/IL-23 antibodies suppressed the progression of HCC (by 70%) in alcohol-fed mice, indicating that targeting IL-17 signaling might provide novel strategies for the treatment of alcohol-induced HCC. CONCLUSIONS: Overall, IL-17A is a tumor-promoting cytokine, which critically regulates alcohol-induced hepatic steatosis, inflammation, fibrosis, and HCC. LAY SUMMARY: IL-17A is a tumor-promoting cytokine, which critically regulates inflammatory responses in macrophages (Kupffer cells and bone-marrow-derived monocytes) and cholesterol synthesis in steatotic hepatocytes in an experimental model of alcohol-induced HCC. Therefore, IL-17A may be a potential therapeutic target for patients with alcohol-induced HCC.
BACKGROUND & AIMS: Chronic alcohol consumption is a leading risk factor for the development of hepatocellular carcinoma (HCC), which is associated with a marked increase in hepatic expression of pro-inflammatory IL-17A and its receptor IL-17RA. METHODS: Genetic deletion and pharmacological blocking were used to characterize the role of IL-17A/IL-17RA signaling in the pathogenesis of HCC in mouse models and human specimens. RESULTS: We demonstrate that the global deletion of the Il-17ra gene suppressed HCC in alcohol-fed diethylnitrosamine-challenged Il-17ra-/- and major urinary protein-urokinase-type plasminogen activator/Il-17ra-/- mice compared with wild-type mice. When the cell-specific role of IL-17RA signaling was examined, the development of HCC was decreased in both alcohol-fed Il-17raΔMΦ and Il-17raΔHep mice devoid of IL-17RA in myeloid cells and hepatocytes, but not in Il-17raΔHSC mice (deficient in IL-17RA in hepatic stellate cells). Deletion of Il-17ra in myeloid cells ameliorated tumorigenesis via suppression of pro-tumorigenic/inflammatory and pro-fibrogenic responses in alcohol-fed Il-17raΔMΦ mice. Remarkably, despite a normal inflammatory response, alcohol-fed Il-17raΔHep mice developed the fewest tumors (compared with Il-17raΔMΦ mice), with reduced steatosis and fibrosis. Steatotic IL-17RA-deficient hepatocytes downregulated the expression of Cxcl1 and other chemokines, exhibited a striking defect in tumor necrosis factor (TNF)/TNF receptor 1-dependent caspase-2-SREBP1/2-DHCR7-mediated cholesterol synthesis, and upregulated the production of antioxidant vitamin D3. The pharmacological blocking of IL-17A/Th-17 cells using anti-IL-12/IL-23 antibodies suppressed the progression of HCC (by 70%) in alcohol-fed mice, indicating that targeting IL-17 signaling might provide novel strategies for the treatment of alcohol-induced HCC. CONCLUSIONS: Overall, IL-17A is a tumor-promoting cytokine, which critically regulates alcohol-induced hepatic steatosis, inflammation, fibrosis, and HCC. LAY SUMMARY: IL-17A is a tumor-promoting cytokine, which critically regulates inflammatory responses in macrophages (Kupffer cells and bone-marrow-derived monocytes) and cholesterol synthesis in steatotic hepatocytes in an experimental model of alcohol-induced HCC. Therefore, IL-17A may be a potential therapeutic target for patients with alcohol-induced HCC.
Authors: Fanli Meng; Kai Wang; Tomonori Aoyama; Sergei I Grivennikov; YongHan Paik; David Scholten; Min Cong; Keiko Iwaisako; Xiao Liu; Mingjun Zhang; Christoph H Österreicher; Felix Stickel; Klaus Ley; David A Brenner; Tatiana Kisseleva Journal: Gastroenterology Date: 2012-06-08 Impact factor: 22.682
Authors: Kepeng Wang; Min Kyoung Kim; Giuseppe Di Caro; Jerry Wong; Shabnam Shalapour; Jun Wan; Wei Zhang; Zhenyu Zhong; Elsa Sanchez-Lopez; Li-Wha Wu; Koji Taniguchi; Ying Feng; Eric Fearon; Sergei I Grivennikov; Michael Karin Journal: Immunity Date: 2014-11-25 Impact factor: 31.745
Authors: Mary A Rodgers; Valerie A Villareal; Esperance A Schaefer; Lee F Peng; Kathleen E Corey; Raymond T Chung; Priscilla L Yang Journal: J Am Chem Soc Date: 2012-04-11 Impact factor: 15.419
Authors: Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter Journal: Ann Intern Med Date: 2013-03-05 Impact factor: 25.391
Authors: Ana L Gomes; Ana Teijeiro; Stefan Burén; Krishna S Tummala; Mahmut Yilmaz; Ari Waisman; Jean-Philippe Theurillat; Cristian Perna; Nabil Djouder Journal: Cancer Cell Date: 2016-07-11 Impact factor: 31.743
Authors: Ju Youn Kim; Lily Q Wang; Valentina C Sladky; Tae Gyu Oh; Junlai Liu; Kaitlyn Trinh; Felix Eichin; Michael Downes; Mojgan Hosseini; Etienne D Jacotot; Ronald M Evans; Andreas Villunger; Michael Karin Journal: Cell Metab Date: 2022-08-29 Impact factor: 31.373